The House debated H.R. 2821, the FDA Modernization Act 3.0, which requires the FDA to issue a rule updating its drug-testing regulations to reference modern, non-animal testing methods in place of animal tests. Members from both parties spoke in support: Representative Buddy Carter, who introduced the bill, said it would make the FDA follow through on allowing alternatives to animal testing, reducing animal suffering and helping new medicines reach patients faster. Representative Troy Carter, a Democratic co-lead, noted that Congress had already authorized such alternatives but the FDA had not yet updated its rules, and said this bill directs the agency to write them. The debate was brief and the bill had bipartisan backing, with no opposing points recorded in the discussion.Written by AI from the debate. Updated .
“I want the House to pass this bill. It tells the FDA to make final rules on testing methods that do not use animals.”
“Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 2821) to require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods. The Clerk read the title of the bill. The text of the bill is as follows:”
Official Congressional Record
Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 2821) to require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods. The Clerk read the title of the bill. The text of the bill is as follows:
“I support this bill. It updates drug testing rules so scientists can use modern testing methods instead of animals whenever possible.”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 2821, led by my colleagues Representative Carter of Georgia and Representative Barragan, which requires the Secretary of HHS to publish rules amending certain regulations by replacing references to ``animal’’ tests, data, studies, models, and research with the broader term ``nonclinical’’ tests, data, studies, models, and research. Biomedical research typically utilizes animal models to explore biological processes, analyze diseases, and explore potential therapies. However, given the concerns and scientific limitations of animal testing, researchers have increasingly turned to new approach methodologies to evaluate drugs when scientifically justified. The scientific community has worked diligently to balance animal welfare concerns and the value of animal tests and research. I am pleased with the progress to date and look forward to seeing continued evidence-driven advancements in this space. I commend the administration for their work to phase out animal testing where it is scientifically appropriate and for achieving the key goals in the first year of implementing the roadmap to reducing animal testing in preclinical safety studies. Mr. Speaker, I appreciate my colleague from Georgia for putting this bill forward, and I reserve the balance of my time.”
Official Congressional Record
Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 2821, led by my colleagues Representative Carter of Georgia and Representative Barragan, which requires the Secretary of HHS to publish rules amending certain regulations by replacing references to ``animal’’ tests, data, studies, models, and research with the broader term ``nonclinical’’ tests, data, studies, models, and research. Biomedical research typically utilizes animal models to explore biological processes, analyze diseases, and explore potential therapies. However, given the concerns and scientific limitations of animal testing, researchers have increasingly turned to new approach methodologies to evaluate drugs when scientifically justified. The scientific community has worked diligently to balance animal welfare concerns and the value of animal tests and research. I am pleased with the progress to date and look forward to seeing continued evidence-driven advancements in this space. I commend the administration for their work to phase out animal testing where it is scientifically appropriate and for achieving the key goals in the first year of implementing the roadmap to reducing animal testing in preclinical safety studies. Mr. Speaker, I appreciate my colleague from Georgia for putting this bill forward, and I reserve the balance of my time.
“I am giving my speaking time to Representative Carter, who is a leader on this issue.”
“Mr. Speaker, I yield such time as he may consume to the gentleman from Georgia (Mr. Carter), a dear friend, a great member of the Energy and Commerce Committee, and a leader in this effort with the FDA. With pharmaceuticals, just about anything that is very important to the American people, he is an absolute leader in that.”
Official Congressional Record
Mr. Speaker, I yield such time as he may consume to the gentleman from Georgia (Mr. Carter), a dear friend, a great member of the Energy and Commerce Committee, and a leader in this effort with the FDA. With pharmaceuticals, just about anything that is very important to the American people, he is an absolute leader in that.
“I want the House to pass this bill. It makes the FDA follow through on allowing modern alternatives to animal testing for new drugs. This will reduce animal suffering and help bring new medicines to patients faster.”
“Mr. Speaker, I thank the gentleman for yielding. Mr. Speaker, I rise today in strong support of my bill, H.R. 2821, the FDA Modernization Act 3.0, bipartisan legislation that ensures the FDA fully embraces modern science while reducing unnecessary animal testing. Many of our families would feel incomplete without the pets and animals that bring unconditional love into our lives. Yet every year, millions of animals, including dogs, man’s best friend, are still subjected to testing in the development of new medicines. As policymakers, we have a responsibility to protect those who cannot protect themselves. That responsibility includes embracing scientific innovation that can reduce unnecessary animal suffering while continuing to deliver safe and effective treatments to patients. In 2022, Congress took an important first step by passing the FDA Modernization Act 2.0. I was proud to help lead that effort. That law gave drug developers the ability to use modern, scientifically validated alternatives to traditional animal testing when appropriate. Congress made its intent clear. We wanted to encourage more effective, more humane, and more innovative approaches to drug development. Unfortunately, the previous administration failed to fully implement the law. Without clear implementation, too many researchers have lacked the certainty they need, and too many animals continue to be used in testing that modern science can increasingly replace. H.R. 2821 ensures the FDA finally carries out the will of Congress. This bill is not lowering standards. It is about raising them. Today’s researchers have access to technologies that simply did not exist a generation ago: advanced human cell models, organ-on-a-chip technology, artificial intelligence, and computational modeling. These innovative tools have the potential to better predict how medicines will perform in humans while reducing reliance on animal testing. Our laws should reflect the science of today, not the science of decades past. Modernizing drug development doesn’t just benefit animals. It benefits patients. By providing greater clarity and encouraging the use of validated alternative methods, we can make the drug development process more efficient. That means fewer unnecessary delays and more innovation. Ultimately, that means lifesaving treatments can reach patients more quickly without compromising the FDA’s rigorous standards for safety and effectiveness. This is a commonsense, bipartisan bill. It reflects a simple principle: We can advance medical innovation while improving animal welfare. Those goals are not in conflict. In fact, they go hand in hand. Mr. Speaker, the FDA Modernization Act 3.0 fulfills the promise Congress made when we passed the FDA Modernization Act 2.0. It ensures that modern science is fully incorporated into our regulatory process. It helps reduce unnecessary animal testing and strengthens American medical innovation. It also helps bring new therapies to patients more efficiently. I urge my colleagues to support H.R. 2821, the FDA Modernization Act 3.0.”
Official Congressional Record
Mr. Speaker, I thank the gentleman for yielding. Mr. Speaker, I rise today in strong support of my bill, H.R. 2821, the FDA Modernization Act 3.0, bipartisan legislation that ensures the FDA fully embraces modern science while reducing unnecessary animal testing. Many of our families would feel incomplete without the pets and animals that bring unconditional love into our lives. Yet every year, millions of animals, including dogs, man’s best friend, are still subjected to testing in the development of new medicines. As policymakers, we have a responsibility to protect those who cannot protect themselves. That responsibility includes embracing scientific innovation that can reduce unnecessary animal suffering while continuing to deliver safe and effective treatments to patients. In 2022, Congress took an important first step by passing the FDA Modernization Act 2.0. I was proud to help lead that effort. That law gave drug developers the ability to use modern, scientifically validated alternatives to traditional animal testing when appropriate. Congress made its intent clear. We wanted to encourage more effective, more humane, and more innovative approaches to drug development. Unfortunately, the previous administration failed to fully implement the law. Without clear implementation, too many researchers have lacked the certainty they need, and too many animals continue to be used in testing that modern science can increasingly replace. H.R. 2821 ensures the FDA finally carries out the will of Congress. This bill is not lowering standards. It is about raising them. Today’s researchers have access to technologies that simply did not exist a generation ago: advanced human cell models, organ-on-a-chip technology, artificial intelligence, and computational modeling. These innovative tools have the potential to better predict how medicines will perform in humans while reducing reliance on animal testing. Our laws should reflect the science of today, not the science of decades past. Modernizing drug development doesn’t just benefit animals. It benefits patients. By providing greater clarity and encouraging the use of validated alternative methods, we can make the drug development process more efficient. That means fewer unnecessary delays and more innovation. Ultimately, that means lifesaving treatments can reach patients more quickly without compromising the FDA’s rigorous standards for safety and effectiveness. This is a commonsense, bipartisan bill. It reflects a simple principle: We can advance medical innovation while improving animal welfare. Those goals are not in conflict. In fact, they go hand in hand. Mr. Speaker, the FDA Modernization Act 3.0 fulfills the promise Congress made when we passed the FDA Modernization Act 2.0. It ensures that modern science is fully incorporated into our regulatory process. It helps reduce unnecessary animal testing and strengthens American medical innovation. It also helps bring new therapies to patients more efficiently. I urge my colleagues to support H.R. 2821, the FDA Modernization Act 3.0.
